What are you looking for?
top

How does MS develop?

KESIMPTA®▼ (ofatumumab) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.1

For full safety information, please refer to the KESIMPTA Summary of Product Characteristics (SmPC).1

MS is a complex, autoimmune condition defined by inflammation, demyelination and axonal damage in the CNS. This damage is caused by B-cells within the lymph nodes, which capture auto-antigens from neurons or their myelin sheaths and, upon presentation to T-cells, direct them to attack the body’s CNS tissue.2,3

To learn more about the pathogenesis of MS and the role of B-cells in the disease, watch this short video.

180397_KESIMPTA_MOA_pathogen_snippet_DR3 VIDEO

CNS, central nervous system; MS, multiple sclerosis; RMS, relapsing multiple sclerosis.

References:

  1. KESIMPTA (ofatumumab) Summary of Product Characteristics.

  2. Pender MP, et al. Curr Allergy Asthma Rep 2007;(4):285–292.

  3. Archelos JJ, et al. Ann Neurol 2000;47:694–706.

Green vertical divider icon
 Safety profile

UK | January 2025 | 443403

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.